SYLVANT (siltuximab), monoclonal antibody

RARE DISEASE - New medicinal product
Opinions on drugs - Posted on Jun 03 2015

Reason for request


Minor clinical benefit in the management of multicentric Castleman’s disease in adults not infected with HIV and HHV-8

  • SYLVANT is the first medicinal product with Marketing Authorisation in the treatment of adult patients with multicentric Castleman’s disease (MCD) not infected with human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8)
  • In these patients, it has shown its efficacy in terms of tumour response (partial and complete).
  • Clinical efficacy data remain limited and have not shown any gain in overall survival.


Clinical Benefit



Clinical Added Value



Therapeutic use


Contact Us

Évaluation des médicaments